Results 61 to 70 of about 4,811,177 (246)

Advances in myelofibrosis: a clinical case approach

Haematologica, 2013
Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and ...
John O. Mascarenhas, Attilio Orazi, Kapil N. Bhalla, Richard E. Champlin, Claire Harrison, Ronald Hoffman   +5 more
doaj   +1 more source

Targeted Therapy of Myelofibrosis [PDF]

Клиническая онкогематология, 2017
Background. Myelofibrosis (primary myelofibrosis, post-essential trombocythemia myelofibrosis, post-polycythemia myelofibrosis) is the most complex and pressing problem among all Ph-negative myeloproliferative diseases. The present article summarizes the
OYu Vinogradova, VA Shuvaev, IS Martynkevich, MM Pankrashkina, MS Fominykh, EV Efremova, KYu Krutikova, LB Polushkina, NN Sharkunov, SV Voloshin, AV Chechetkin   +10 more
doaj   +1 more source

TP53 mutations and Polymorphisms in Primary Myelofibrosis, [PDF]

Blood, 2011
Abstract Abstract 3840 Background: Patients with myeloproliferative neoplasms (MPN) harbor a multitude of somatic mutations involving JAK2, MPL, LNK, CBL, TET2, ASXL1, IDH1, IDH2, EZH2, DNMT3A, IKZF1 and TP53.
Rhett P. Ketterling, Animesh Pardanani, Ryan A. Knudson, Lori A. Erickson, Christy Finke, David S. Viswanatha, Terra L. Lasho, Ayalew Tefferi, Sania S Raza   +8 more
openaire   +4 more sources

Adiponectin Assists Thrombopoietic Agents in ITP Treatment by Enhancing Myosin‐9/Rab6A‐Mediated Trafficking of c‐Mpl in MKs

Advanced Science, EarlyView.
This study revealed that adiponectin facilitates the therapeutic efficiency of thrombopoietic agents by stimulating the membrane trafficking of c‐Mpl in MKs, which provides a point for ITP therapy. Moreover, a novel c‐Mpl trafficking mechanism based on the Myosin‐9/Rab6A complex is constructed. These findings provide new insights into the applicability
Xin Zhao, Huixian Ma, Guosheng Li, Jilong Xiao, Zhiyu Shi, Mingying Li, Xinguang Liu, Tao Sun, Chunyan Ji   +8 more
wiley   +1 more source

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model

Blood Cancer Journal, 2019
Among 1306 patients with primary myelofibrosis (PMF), we sought to identify risk factors that predicted leukemic transformation (LT) in the first 5 years of disease and also over the course of the disease.
Rangit R. Vallapureddy, M. Mudireddy, D. Penna, T. Lasho, C. Finke, C. Hanson, R. Ketterling, K. Begna, N. Gangat, A. Pardanani, A. Tefferi   +10 more
semanticscholar   +1 more source

Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

American Journal of Hematology, EarlyView.
ABSTRACT Selecting the optimal donor is crucial for optimizing results of allogeneic hematopoietic cell transplantation (allo‐HCT). We analyzed outcomes based on donor type in 2809 myelofibrosis (MF) patients undergoing first allo‐HCT between 2015 and 2021 at EBMT centers.
Juan Carlos Hernández‐Boluda, Vipul Sheth, Simona Iacobelli, Linda Koster, Nicolaus Kröger, Patrizia Chiusolo, Thomas Schroeder, Marie Robin, Massimiliano Gambella, Didier Blaise, Henrik Sengeloev, Jakob Passweg, Mattias Stelljes, Robert Zeiser, Ibrahim Yakoub‐Agha, Andrew Clark, Urpu Salmenniemi, Piero Galieni, Werner Rabisch, Kavita Raj, Joanna Drozd‐Sokolowska, Giorgia Battipaglia, Nicola Polverelli, Tomasz Czerw, Donal P. McLornan   +24 more
wiley   +1 more source

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

Haematologica, 2011
Background The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under ...
Brady L. Stein, Donna M. Williams, Christine O’Keefe, Ophelia Rogers, Roxann G. Ingersoll, Jerry L. Spivak, Amit Verma, Jarek P. Maciejewski, Michael A. McDevitt, Alison R. Moliterno   +9 more
doaj   +1 more source

Triple A Plus (AAA+) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients

American Journal of Hematology, EarlyView.
A new risk model for essential thrombocythemia that is based on complete blood cell count‐derived parameters and host‐related factors. ABSTRACT Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple‐A (AAA) prognostic score.
Ayalew Tefferi, Giuseppe G. Loscocco, Lior Rokach, Tamar Tadmor, Priyansh Faldu, Guy Melamed, Hilel Alapi, Maymona Abdelmagid, Rania M. Abdelaziz, Muhammad Yousuf, Merry Nakhleh, Animesh Pardanani, Kebede H. Begna, Mirnal M. Patnaik, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Kaaren K. Reichard, Rong He, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi   +21 more
wiley   +1 more source

Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and management

American journal of hematology/oncology, 2018
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional disease features include bone marrow ...
A. Tefferi
semanticscholar   +1 more source

Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

British Journal of Haematology, 2022
a peptide a key regulator of iron in an hepcidin levels can restricted erythro-poiesis and anaemia. myeloproliferative neoplasm (MPN) in we in 99 patients 49 and (SMF) Twenty- four of these patients ruxolitinib a JAK1/2 inhibitor for treatment of MF.
A. Zhou, Tim Kong, Jared S. Fowles, Chun‐Ling Jung, Maggie J. Allen, Daniel A. C. Fisher, M. Fulbright, E. Nemeth, T. Ganz, S. Oh   +9 more
semanticscholar   +1 more source